They highlight the importance of integrating various computational tools, structural information, and experimental validation in the drug discovery process, particularly for targets like BACE-1 involved in Alzheimer’s disease. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.